Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Combination Regimens May Expand Options for HR+ Breast Cancer Post-CDK4/6 Inhibitors

August 23rd 2024

Shipra Gandhi, MD, discusses factors influencing treatment decisions for patients with HR-positive breast cancer who have progressed on CDK4/6 inhibitors.

ODAC Vote Aims to Introduce Clarity on Phase of Treatment Benefits in Resectable NSCLC

August 22nd 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

Future Perioperative Trial Designs in NSCLC Need Adjustments Per FDA ODAC Consensus

August 20th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

Sacituzumab Govitecan Displays Activity in Advanced/Metastatic Endometrial Cancer

August 19th 2024

Treatment with sacituzumab govitecan led to antitumor activity in endometrial cancer and TROP-2 expression did not appear to affect response to the agent.

Subsequent Therapy Shows No Difference in OS Following IO/TKI-Based Treatment in RCC

August 19th 2024

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

Adagrasib/Cetuximab Combo Marks the Beginning of the RAS-Targeting Era in CRC

August 19th 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

FDA Grants Priority Review to Vimseltinib in Tenosynovial Giant Cell Tumor

August 16th 2024

The FDA has accepted an NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor, with a PDUFA date of February 17, 2025.

Tafasitamab Plus R2 Improves PFS in Relapsed/Refractory Follicular Lymphoma

August 16th 2024

Tafasitamab plus lenalidomide and rituximab improved progression-free survival vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Acalabrutinib With/Without Obinutuzumab Is Effective in Higher-Risk Chronic Lymphocytic Leukemia

August 16th 2024

Acalabrutinib-containing regimens demonstrated long-term efficacy with a tolerable safety profile in higher-risk chronic lymphocytic leukemia.

FDA Approves Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

August 15th 2024

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

An Embarrassment of Riches in Oncology With Wayward Decision Support: A Recipe for Disaster?

August 15th 2024

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations

August 15th 2024

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Cannabis-Use Disorder Demonstrates a Link With Developing Head and Neck Cancer

August 14th 2024

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

China’s NMPA Grants Breakthrough Therapy Designation to 9MW2821 in Advanced Urothelial Cancer

August 12th 2024

The Nectin-4–directed antibody-drug conjugate 9MW2821 has received breakthrough therapy designation in China for pretreated, advanced urothelial carcinoma.

Rhenium Obisbemeda Demonstrates Safety and Feasibility in Leptomeningeal Metastases

August 12th 2024

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

RLY-2608 Uses PI3Kα Mutant–Specific Inhibition to More Safely Treat Breast Cancer and Other Solid Tumors

August 12th 2024

Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.

Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?

August 11th 2024

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Improved Patient Selection Will Pave the Way for ADC Optimization in HER2-Low and -Ultralow Breast Cancer

August 9th 2024

Erika P. Hamilton, MD, discusses the implications of the DESTINY-Breast06 trial for patients with HER2-low and -ultralow breast cancer.

Orelabrutinib Plus Lenalidomide and Rituximab Demonstrates Efficacy in Frontline MCL

August 9th 2024

Orelabrutinib in combination with lenalidomide and rituximab was safe and active in treatment-naive mantle cell lymphoma.

Treatment After Progression on CDK4/6 Inhibitors Requires Careful Consideration in HR+/HER2– mBC

August 8th 2024

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.